- Business Wire•58 minutes agoGlancy Prongay & Murray LLP Commences Investigation on Behalf of Momenta Pharmaceuticals, Inc. Investors
Glancy Prongay & Murray LLP announces an investigation on behalf of Momenta Pharmaceuticals, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
- Motley Fool•19 hours ago
The attempted approval of the three-times-weekly version of Glatopa dominated the earnings conference call.
Clovis Oncology, Inc. (CLVS) reported fourth-quarter 2016 loss of $1.83 per share, wider than the Zacks Consensus Estimate of a loss of $1.65.
MNTA : Summary for Momenta Pharmaceuticals, Inc. - Yahoo Finance
Momenta Pharmaceuticals, Inc. (MNTA)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
|Bid||15.05 x 200|
|Ask||15.10 x 500|
|Day's Range||14.90 - 15.15|
|52 Week Range||7.86 - 19.90|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||-11.21|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|